Prime Highlights
- Halliburton beat both Q1 2026 earnings and revenue estimates, reinforcing investor confidence.
- Wall Street raised price targets, but Middle East tensions could delay the projected 2027 earnings recovery.
Key Facts
- Halliburton is one of the world’s largest oilfield services companies, supporting global energy across drilling, evaluation, and production.
- Q1 2026 EPS of 55 cents and revenue of $5.402 billion both surpassed analyst forecasts.
Background
The first quarter results of 2026 were way above expectations for Halliburton. The company reported earnings of 55 cents per share, which exceeded the analyst estimate of 50 cents. The company achieved revenue of $5.402 billion, which exceeded the expected amount of $5.305 billion while experiencing a slight decline of 0.4% from the previous year. The results show that the oilfield services company maintains its ability to exceed market expectations despite facing difficult conditions.
Investor attention remains firmly on the company’s Middle East exposure, a theme analysts flagged as central to the energy services industry this earnings season. One Wall Street analyst noted in the first week of April that Halliburton carries less risk from regional activity slowdowns compared to its peers, while raising the stock’s price target from 35 to 39 with a neutral rating. Several other major financial institutions also raised their price targets in the weeks leading up to the report.
The broader question on investors’ minds is whether ongoing tensions involving Iran could delay an anticipated earnings recovery projected for 2027. While the company has seen declining earnings and revenue across the past seven quarters, the consistent trend of beating estimates keeps confidence intact.
Halliburton shares rose 1% to $37.04 in early Tuesday trading, extending a 30% gain so far in 2026. The stock has pulled back slightly over the past three weeks alongside easing crude prices and is now testing a key technical support level. Analysts point to a decisive move above $37.74 as a potential buying opportunity. The stock carries an IBD Composite Rating of 80.
